{"id":"NCT01952015","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","officialTitle":"A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-21","primaryCompletion":"2016-03-15","completion":"2016-03-15","firstPosted":"2013-09-27","resultsPosted":"2019-03-15","lastUpdate":"2019-03-15"},"enrollment":12,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":[]}],"arms":[{"label":"AIN457","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to assess efficacy and safety data of secukinumab in Japanese subjects with generalized pustular psoriasis (GPP). This study was expected to support the filing of secukinumab in the indication of pustular psoriasis in Japan.","primaryOutcome":{"measure":"Number of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set)","timeFrame":"16 weeks","effectByArm":[{"arm":"AIN457","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":12},"commonTop":["NASOPHARYNGITIS","DIABETES MELLITUS","ARTHRALGIA","URTICARIA","ANAEMIA"]}}